GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Premas Biotech is the developer of the technology for the Covid-19 vaccine and a shareholder in Oravax Medical
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
The US $ 192.5 mn US government contract will help fund the centre of excellence to boost the domestic supply of critically needed laboratory plastics
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
